Related Experiment Video
Updated: May 10, 2025
Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells
Published on: February 27, 2020
[The effect of acetylamide synthetic peptide HLDF-6 on cell differentiation in breast cancer]
A A Studenikina1,2, E D Mangazeeva1, A P Bogachuk3
1Novosibirsk State Medical University, Novosibirsk, Russia.
Abstract:
The development of drugs with the ability to increase differentiation and reduce tumor malignancy is one of the promising directions in the treatment of breast cancer (BC). As such, Human Leukemia Differentiation Factor (HLDF), a protein consisting of 54 amino acids and contributing to an increase in the degree of differentiation of invasive ductal breast carcinoma cells, can be used. The key disadvantage of the full-size HLDF is its rapid biodegradation. In this connection, the acetylamide form of the peptide (HLDF-6) was synthesized to protect against hydrolysis.
Objective:
To evaluate the effect of HLDF-6 on cell differentiation in various molecular biological subtypes of breast cancer.
Material And Methods:
The relative content of tumor cells of various degrees of differentiation in biopsies of 33 women with breast cancer when exposed to HLDF-6 tumor was evaluated.
Results:
HLDF-6 significantly increases the relative content of differentiated cells in the luminal B HER2-negative subtype of breast cancer, without significantly affecting the cells of patients with luminal A and basal-like subtypes.
Conclusion:
The study revealed the prospects of using HLDF-6 as part of differentiating therapy in patients with luminal B HER2-negative subtype of breast cancer.
